#CHRS hashtag - Bluesky

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114) Coherus Oncology (NASDAQ: CHRS) announced publication in Molecular Cancer Therapeutics describing preclinical and first-in-human biomarker data for investigational anti-CCR8 antibody tagmokitug (CHS-114).Key findings: picomolar binding affinity, no off-target binding, selective depletion of CCR8+ regulatory T cells, high prevalence and density of CCR8 across many solid tumors, tumor regression in mouse models with enhanced activity when combined with anti-PD-1, and translational proof-of-mechanism showing selective CCR8+ Treg reductions in patients.The publication supports ongoing clinical development of tagmokitug in combination with toripalimab across multiple solid tumor settings.

2 months ago

#CHRS Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

www.stocktitan.net/news/CHRS/coherus-oncolo...

0 0 0 0

Certified Human Resource Specialist (CHRS®) (Recruitment) – HRSINGAPORE Acquire essential recruitment skills in Singapore with the CHRS® (Recruitment) course. Learn job analysis, hiring laws, and effective staffing strategies.

3 months ago

𝘔𝘢𝘴𝘵𝘦𝘳 𝘵𝘩𝘦 𝘦𝘯𝘥-𝘵𝘰-𝘦𝘯𝘥 𝘳𝘦𝘤𝘳𝘶𝘪𝘵𝘮𝘦𝘯𝘵 𝘱𝘳𝘰𝘤𝘦𝘴𝘴 𝘢𝘯𝘥 𝘣𝘶𝘪𝘭𝘥 𝘢 𝘱𝘰𝘸𝘦𝘳𝘧𝘶𝘭 𝘵𝘢𝘭𝘦𝘯𝘵 𝘱𝘪𝘱𝘦𝘭𝘪𝘯𝘦. 🔍

Earn the specialist CHRS® (Recruitment) title.

Learn more: hrsingapore.org/certified-human-resource-specialist-recruitment/

#Recruitment #TalentAcquisition #HRCertification #CHRS #HRSpecialist #HRTraining #HRSingap

0 0 0 0

Certified Human Resource Specialist (CHRS®) (Recruitment) – HRSINGAPORE Acquire essential recruitment skills in Singapore with the CHRS® (Recruitment) course. Learn job analysis, hiring laws, and effective staffing strategies.

3 months ago

𝘔𝘢𝘴𝘵𝘦𝘳 𝘵𝘩𝘦 𝘦𝘯𝘥-𝘵𝘰-𝘦𝘯𝘥 𝘳𝘦𝘤𝘳𝘶𝘪𝘵𝘮𝘦𝘯𝘵 𝘱𝘳𝘰𝘤𝘦𝘴𝘴 𝘢𝘯𝘥 𝘣𝘶𝘪𝘭𝘥 𝘢 𝘱𝘰𝘸𝘦𝘳𝘧𝘶𝘭 𝘵𝘢𝘭𝘦𝘯𝘵 𝘱𝘪𝘱𝘦𝘭𝘪𝘯𝘦. 🔍

Earn the specialist CHRS® (Recruitment) title.

Learn more: hrsingapore.org/certified-human-resource-specialist-recruitment/

#Recruitment #TalentAcquisition #HRCertification #CHRS #HRSpecialist #HRTraining #HRSingap

0 0 0 0

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma Coherus (NASDAQ: CHRS) reported six-year follow-up from the Phase 3 JUPITER-02 trial showing LOQTORZI (toripalimab-tpzi) plus gemcitabine and cisplatin achieved a median overall survival of 64.8 months vs 33.7 months for chemotherapy alone (31-month improvement; HR 0.62; 95% CI 0.45–0.85).Results presented at ESMO Asia 2025 reinforce LOQTORZI plus chemotherapy as a first-line option for recurrent or metastatic nasopharyngeal carcinoma and summarize key safety findings including immune-mediated adverse events.

3 months ago

#CHRS Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

www.stocktitan.net/news/CHRS/coherus-announ...

0 0 0 0

Yale Cancer Center

@yalecancer.bsky.social

4 months ago

Clonal Hematopoiesis Risk Score (CHRS) Evaluation as a Prognostic Marker for Death in Cardio-Oncology Cohort

A Yale study led by @jennkwanmdphd.bsky.social shows clonal hematopoiesis of indeterminate potential #CHIP doubles mortality risk in pts with #cancer, but clonal hematopoiesis risk score #CHRS doesn’t predict survival in this group.
sciencedirect.com/science/arti...
@jaccjournals.bsky.social

0 0 0 0

4 months ago

#CHRS Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

www.stocktitan.net/news/CHRS/coherus-oncolo...

0 0 0 0

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update Coherus Oncology (NASDAQ: CHRS) reported Q3 2025 results and a business update on Nov 6, 2025. LOQTORZI net revenue was $11.2M in Q3, up 12% QoQ and 92% YoY; total net revenue from continuing operations was $11.6M for the quarter. Cash, cash equivalents and marketable securities were $191.7M as of Sept 30, 2025. R&D spending rose to $27.3M in Q3 while SG&A declined to $24.9M. Net loss from continuing operations was $44.5M, or $(0.38) per share, with non-GAAP net loss of $38.9M. Pipeline progress includes expansion of CHS-114 into colorectal cancer and multiple 2026 readouts for CHS-114 and casdozokitug.

4 months ago

#CHRS Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CHRS/coherus-oncolo...

0 0 0 0

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Coherus Oncology (NASDAQ: CHRS) will present a poster at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), Nov 5-9, 2025, in National Harbor, Maryland. Abstract #640 reports that CHS-114, an anti-CCR8 cytolytic monoclonal antibody, “demonstrates selective intratumoral Treg depletion and favorable immune remodeling” in participants with advanced solid tumors. The poster presentation is scheduled for Saturday, November 8, 2025 at Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center.Additionally, CHS-114 will be featured in SITC’s webinar series "Targets for Cancer IO: A Deep Dive" on October 22, 2025, 12:00–2:00 PM ET, covering CCR8 biology and clinical results, with Coherus faculty Rosh Dias, MD and Varun Kapoor, PhD.

6 months ago

#CHRS Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

www.stocktitan.net/news/CHRS/coherus-oncolo...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

7 months ago

Coherus (CHRS) Q2 Revenue Jumps 10% | The Motley Fool

#CHRS #101f653f-fd4f-4a28-9c45-8d9e8717dc81 #data-news

Origin | Interest | Match

0 0 0 0

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update Coherus Oncology (NASDAQ:CHRS) reported Q2 2025 financial results, highlighting $10.0 million in LOQTORZI net revenue, a 36% increase from Q1 2025. The company ended Q2 with $238 million in cash and completed the UDENYCA divestiture for $483.4 million, with potential milestone payments of up to $75 million.Key pipeline developments include progress on CHS-114, a cytolytic CCR8 antibody, and casdozokitug, a first-in-class IL-27 antagonist, with data readouts expected in 1H 2026. The company reported a Q2 net loss from continuing operations of $44.9 million ($0.39 per share), while net income from discontinued operations was $342.6 million ($2.95 per share), primarily due to the UDENYCA divestiture gain.

7 months ago

#CHRS Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CHRS/coherus-oncolo...

0 0 0 0

9 months ago

📈 Step up as a strategic HR leader with HRSINGAPORE’s Certified Human Resource Supervisor (CHRS®) course! Master HR planning, analytics, employment law & more in just 8 days 🧑‍💼💡

Sign Up Now 👉🏻 hrsingapore.org/chrs

#CHRS #HRSupervisor #HRLeadership #HRCertification #HRSINGAPORE #HRTraining

0 0 0 0

9 months ago

📈 Step up as a strategic HR leader with HRSINGAPORE’s Certified Human Resource Supervisor (CHRS®) course! Master HR planning, analytics, employment law & more in just 8 days 🧑‍💼💡

Sign Up Now 👉🏻 hrsingapore.org/chrs

#CHRS #HRSupervisor #HRLeadership #HRCertification #HRSINGAPORE #HRTraining

0 0 0 0

9 months ago

💼 Master payroll with HRSINGAPORE’s CHRS® (Payroll) certification! Learn CPF, IRAS, salary processing, leave admin & more in this practical 8-day course. Perfect for HR pros handling payroll in SG 🇸🇬

👉🏻 hrsingapore.org/chrs-payroll

#PayrollTraining #HRPayroll #CPFCompliance #SingaporeHR #CHRS

0 0 0 0

9 months ago

💼 Master payroll with HRSINGAPORE’s CHRS® (Payroll) certification! Learn CPF, IRAS, salary processing, leave admin & more in this practical 8-day course. Perfect for HR pros handling payroll in SG 🇸🇬

👉🏻 hrsingapore.org/chrs-payroll

#PayrollTraining #HRPayroll #CPFCompliance #SingaporeHR #CHRS

0 0 0 0

9 months ago

🚀 Step up as a confident HR leader with the Certified Human Resource Supervisor (CHRS®) programme! Gain key skills in supervision, performance & conflict management. 🌟

🔗 hrsingapore.org/chrs

#HRTraining #HRSINGAPORE #CHRS #HRSupervisor #HRDevelopment #Leadership #SingaporeHR

0 0 0 0

9 months ago

🚀 Step up as a confident HR leader with the Certified Human Resource Supervisor (CHRS®) programme! Gain key skills in supervision, performance & conflict management. 🌟

🔗 hrsingapore.org/chrs

#HRTraining #HRSINGAPORE #CHRS #HRSupervisor #HRDevelopment #Leadership #SingaporeHR

0 0 0 0

9 months ago

Sharpen your recruitment expertise with HRSINGAPORE’s CHRS® (Recruitment). This specialist certification builds practical skills in talent acquisition, interviewing, onboarding, and recruitment strategies across 7 focused modules. More at hrsingapore.org/certified-hu...

#CHRS #Recruitment #Training

0 0 0 0

9 months ago

Sharpen your recruitment expertise with HRSINGAPORE’s CHRS® (Recruitment). This specialist certification builds practical skills in talent acquisition, interviewing, onboarding, and recruitment strategies across 7 focused modules. More at hrsingapore.org/certified-hu...

#CHRS #Recruitment #Training

0 0 0 0

Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics Coherus BioSciences (NASDAQ: CHRS) has rebranded as Coherus Oncology to reflect its strategic focus on innovative cancer immunotherapy treatments. The company is developing novel combination therapies centered around LOQTORZI® (toripalimab-tpzi), an FDA-approved PD-1 inhibitor for nasopharyngeal carcinoma. Their pipeline includes CHS-114, a selective CCR8 antibody targeting tumor regulatory T cells, and casdozokitug, a first-in-class IL-27 antagonist showing promise in various cancers. The company is backed by a distinguished Scientific Advisory Board and Board of Directors, featuring experts from leading institutions and organizations including the Cancer Research Institute, Merck, and Bristol Myers Squibb.

10 months ago

#CHRS Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics

www.stocktitan.net/news/CHRS/coherus-comple...

0 0 0 0

Breakthrough Cancer Trial Launches: LOQTORZI Combination Study Targets 4 Major Cancer Types Novel METTL3 inhibitor combines with PD-1 therapy in 188-patient study targeting lung, head and neck, melanoma, and endometrial cancers. See trial details.

10 months ago

#CHRS Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)

www.stocktitan.net/news/CHRS/coherus-announ...

0 0 0 0

10 months ago

👩‍💼 Step up in your HR journey with the Certified Human Resource Supervisor (𝘊𝘏𝘙𝘚®) course starting 28 June 2025! 🌱 Boost your skills & career with expert-led modules! 🧠✨

👉 Register now: hrsingapore.org/chrs/

#HRSingapore #CHRS #HRLeadership #ProfessionalGrowth #SingaporeHR #HRCertification

0 0 0 0

Expansion of multiple CD4+ T cell lineages in lymphocytic variant hypereosinophilic syndrome - PubMed These data provide further evidence for direct involvement of the aberrant T cell populations in disease pathogenesis in LHES and a rationale for further exploration of T cell-directed therapies.

10 months ago

👩‍💼 Step up in your HR journey with the Certified Human Resource Supervisor (𝘊𝘏𝘙𝘚®) course starting 28 June 2025! 🌱 Boost your skills & career with expert-led modules! 🧠✨

👉 Register now: hrsingapore.org/chrs/

#HRSingapore #CHRS #HRLeadership #ProfessionalGrowth #SingaporeHR #HRCertification

0 0 0 0

@spontonic.bsky.social

10 months ago

#CHRS #ZLAB many others..... a non-oncology indication for anti- #CCR8? pubmed.ncbi.nlm.nih.gov/40350095/

0 0 0 0

@spontonic.bsky.social

10 months ago

Tumor-Derived Immunoglobulin-Like Transcript 4 Promotes Postoperative Relapse via Inducing Vasculogenic Mimicry through MAPK/ERK Signaling in Hepatocellular Carcinoma - PubMed The efficacy of conventional anti-angiogenesis drugs is usually low in treating hepatocellular carcinoma (HCC). Therefore, there is an urgent need to find new precise therapeutic targets and to develo...

:-) Agreed. But if I was at #CHRS, I'd be keeping an eye open for any follow up to this study. Talk about intriguing! pubmed.ncbi.nlm.nih.gov/39233275/

1 0 0 0

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update Coherus BioSciences (CHRS) reported Q1 2025 financial results, highlighting its strategic transformation to innovative oncology. LOQTORZI generated net revenue of $7.3 million with >15% patient demand growth vs Q4 2024. The company completed the UDENYCA divestiture for up to $558.4 million, receiving $483.4 million upfront. Q1 results showed net loss from continuing operations of $47.4 million ($0.41/share). Key pipeline developments include positive Phase 1b data for CHS-114 in head and neck cancer and ongoing trials for casdozokitug combination therapy. Cash position was $82.4 million as of March 31, 2025. The company is advancing its oncology portfolio with LOQTORZI, the only FDA-approved treatment for nasopharyngeal carcinoma, while progressing clinical trials for CHS-114 and casdozokitug with data readouts expected in 2026.

10 months ago

#CHRS Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CHRS/coherus-bio-sc...

0 0 0 0

10 months ago

Master the art of payroll in SG! 💰🧾

From salary structure to legal compliance — get certified now! 📈
Perfect for payroll pros looking to level up! 💼

15th Intake Starts 10th May (Every Sat) 👉 hrsingapore.org/chrs-payroll/

#CHRS #PayrollPro #HRSingapore #HRSkills #HRCertification #HRTraining

1 0 0 0

10 months ago

Master the art of payroll in SG! 💰🧾

From salary structure to legal compliance — get certified now! 📈
Perfect for payroll pros looking to level up! 💼

15th Intake Starts 10th May (Every Sat) 👉 hrsingapore.org/chrs-payroll/

#CHRS #PayrollPro #HRSingapore #HRSkills #HRCertification #HRTraining

0 0 0 0

11 months ago

💰 Ready to master payroll like a pro? Join our CHRS® (Payroll) course starting 10 May 2025 (Sat) & get certified! 📅💼
Earn your title & boost your HR career! 🏅

👉 hrsingapore.org/chrs-payroll/

#PayrollPro #HRTraining #CHRS #HRSingapore #HRSkills #CareerBoost

0 0 0 0